{
  "report_rows": [
    {
      "kpi": "Yeztugo Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$245M vs. cons $227M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "HIV Total Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$5,480M vs. cons $5,396M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Trodelvy Revenue (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~$415M vs. cons $425M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Total Product Sales (FY2026)",
      "prediction": "BETTER",
      "answer": "guide ~$30.5-30.8B vs. cons $30.42B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Yeztugo (FY2026)",
      "prediction": "BETTER",
      "answer": "guide ~$1.05-1.10B vs. cons $1.050B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "HIV Total Sales Growth (FY2026)",
      "prediction": "UNCHANGED",
      "answer": "guide ~8% YoY vs. cons ~8% YoY",
      "confidence": "HIGH"
    },
    {
      "kpi": "Veklury (FY2026)",
      "prediction": "UNCHANGED",
      "answer": "guide ~$600M vs. cons $582M",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 4.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 2.5,
  "day5_path": "FADE",
  "day5_rationale": "FADE \u2014 Archetype A low-bar quarters historically fade 5-day as sell-side digests modest raise; Trodelvy miss and slightly negative HIV revision trend limit follow-through",
  "day5_confidence": "MEDIUM"
}